Shares of Sartorius AG (F:SATG) moved higher after Berenberg upgraded the German laboratory and bioprocessing supplier to "buy" from "hold" and increased its price objective to €250 from €215. The broker described the recent pullback following first-quarter results as an overreaction and argued the stock now presents an attractive entry point.
Berenberg highlighted that the share price fell roughly 10% after the company's April 23 first-quarter report. The bank attributed that selloff to sector rotation and investor unease about Sartorius not explicitly committing to double-digit growth in bioprocessing consumables in 2026.
Analysts at Berenberg said the negative cycle of earnings revisions has probably ended and that risks are more skewed to the upside going forward. Their detailed forecasts call for continued expansion across the group's core bioprocessing activities and the wider business.
Key top-line and margin projections in Berenberg's note include:
- Bioprocessing division revenue growth of 9% in 2026, which the bank notes is at the top end of the company's 6-10% guidance range.
- Group revenue growth of 8% in 2026, also at the upper end of Sartorius's 5-9% guidance.
- Revenue rising from €3.75 billion in 2026 to €4.12 billion in 2027 and €4.54 billion in 2028.
- Adjusted EBITDA margin expanding from 30.1% in 2026 to 30.8% in 2027 and 31.6% in 2028.
- Adjusted earnings per share of €5.38 in 2026, €6.40 in 2027 and €7.38 in 2028, implying a compound annual growth rate of 17.2%.
On valuation, Berenberg observed the stock currently trades at 34 times 2027 estimated earnings and at 17 times enterprise value to EBITDA. The broker's €250 target corresponds to multiples of about 40 times price-to-earnings and 20 times EV/EBITDA under a blended discounted cash flow and multiples methodology.
The note also cited supportive signals from peers. Danaher reported high single-digit core bioprocessing revenue growth in the first quarter of 2026 and said equipment orders rose more than 30% year-on-year, marking the first annual increase in nearly two years. Thermo Fisher reported a robust quarter in its bioproduction business, which helped drive growth in its pharma and biotech segment.
Berenberg flagged a common theme from those peer updates: U.S. drug manufacturing reshoring is expected to act as a tailwind for equipment demand beginning in 2027, with some early expansion orders and signed contracts already visible.
The broker's balance-sheet and cash-flow expectations for Sartorius include a decline in net debt from €3.58 billion in 2026 to €3.24 billion in 2027 and €2.77 billion in 2028. Return on capital employed is forecast to climb from 8% to 11.1% over the same period. Free cash flow per share is projected at €3.30 in 2026, €4.62 in 2027 and €6.39 in 2028.
Market data cited in the note put the shares within a 52-week range of €177.50 to €265.30. Sartorius's market capitalisation was listed at €13.87 billion and its enterprise value at €22.01 billion.
Summary of Berenberg's position and market context:
- Berenberg upgraded Sartorius to buy and raised the price target to €250, viewing the post-earnings drop as an overreaction tied to sector rotation and concerns over 2026 consumables growth guidance.
- The bank's forecasts place Sartorius at the upper end of its public guidance ranges for 2026, with continued revenue, margin and cash-flow improvement projected through 2028.
- Peer company results from Danaher and Thermo Fisher were cited as supporting evidence, and both firms pointed to reshoring dynamics in the U.S. as a potential equipment demand driver from 2027 onward.
Investors should weigh the upgraded rating and raised target against the risks that led to the recent selloff, including investor sensitivity to near-term guidance language and sector rotation dynamics.